Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma

Digestive Diseases

Volumn 29, Issue 3, 2011, Pages 289-302

  Kudo, Masatoshi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Brivanib; Complete remission; Hepatocellular carcinoma; Molecular targeted agent; Sorafenib; Sunitinib

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ARRY 142866; AS 703026; AVE 1642; AXITINIB; BAY 869766; BEVACIZUMAB; BIIB 022; BRIVANIB; CEDIRANIB; CETUXIMAB; CIXUTUMUMAB; E 6201; ERLOTINIB; EVEROLIMUS; GEFITINIB; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; LAPATINIB; LENVATINIB; LINIFANIB; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; ORANTINIB; PANITUMUMAB; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RAMUCIRUMAB; RAPAMYCIN; RDEA 119; RG 7321; SELUMETINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; TIGATUZUMAB; TIVANTINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ADJUVANT THERAPY; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ASTHENIA; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; WOUND INFECTION;

BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; PYRIDINES; SIGNAL TRANSDUCTION;

EID: 80051726301     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000327562     Document Type: Conference Paper

References (66)

1. Farazi PA, DePinho RA: Hepatocellular carcinoma pathogenesis: From genes to environment. Nat Rev Cancer 2006; 6:674-687. (Pubitemid 44286000)
2. Minguez B, Tovar V, Chiang D, et al: Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol 2009; 25: 186-194.
3. Villanueva A, Newell P, Chiang DY, et al: Genomics and signaling pathways in hepatocellular carcinoma, Semin Liver Dis 2007; 27: 55-76.
4. Laurent-Puig P, Zucman-Rossi J: Genetics of hepatocellular tumors. Oncogene 2006; 25: 3778-3786. (Pubitemid 43980473)
5. Llovet JM, Bruix J: Molecular-targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48: 1312-1327.
6. Hopfner M, Shuppan D, Scherubl H: Growth factor receptors and related signaling pathways as target for novel treatment strategies of hepatocellular cancer. World J Gastroenterol 2008; 14: 1-14. (Pubitemid 351314320)
7. Campbell JS, Hughes SD, Gilbertson DG, et al: Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci USA 2005; 102: 3389-3394. (Pubitemid 40328055)
8. Ogasawara S, Yano H, Iemura A, et al: Expression of basic fibroblast growth factor and its receptors and their relationship to proliferation of human hepatocellular carcinoma cell lines. Hepatology 1996; 24: 198-205. (Pubitemid 26249434)
9. Kudo M: Hepatocellular carcinoma 2009 and beyond: From the surveillance to molecular-targeted therapy. Oncology 2008; 75:S1-S12.
10. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
11. Spangenberg HC, Thimme R, Blum HE: Targeted therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2009; 6: 423-432.
12. Roberts PJ, Der CJ: Targeting the Ras-MEKERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26: 3291-3310. (Pubitemid 46763022)
13. Schmidt CM, McKillop IH, Cahill PA, et al: Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem Biophys Res Commun 1997; 236: 54-58. (Pubitemid 27341838)
14. Huynh H, Nguen TT, Chow KH, et al: Overexpression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: Its role in tumor progression and apoptosis. BMC Gastroenterol 2003; 3: 19.
15. Calvisi DF, Ladu S, Gorden A, et al: Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006; 130: 1117-1128.
16. Bos JL: Ras oncogenes in human cancer: Review. Cancer Res 1989; 49: 4682-4689. (Pubitemid 19213607)
17. Beeram M, Patnaik A, Rowinsky EK: Ras: A strategic target for therapeutic development against cancer. J Clin Oncol 2005; 23: 6771-6790. (Pubitemid 46194105)
18. Tannapfel A, Sommerer F, Benicke M, et al: Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003; 52: 706-712. (Pubitemid 36528874)
19. Jenke HS, Deml E, Oesterle D: C-raf expression in early rat liver tumorigenesis after promotion with polychlorinated biphenyls or phenobarbital. Xenobiotica 1994; 24: 569-580. (Pubitemid 24207920)
20. Beer DG, Neveu MJ, Paul DL, et al: Expression of the c-raf protooncogene,α-glutamyltranspeptidase, and gap junction protein in rat liver neoplasms. Cancer Res 1998; 48: 1610-1617.
21. Hwang YH, Choi JY, Kim S, et al: Over-expression c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma. Hepatol Res 2004; 29: 113-121. (Pubitemid 38667508)
22. Wilhelm SM, Adnane L, Newell P, et al: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7: 3129-3140.
23. Ohren JF, Chen H, Pavlovsky A, et al: Structures of human MAP kinase kinase 1(MEK1) and MEK2 describe novel non-competitive kinase inhibition. Nat Struct Mol Biol 2004; 11: 1192-1197.
24. Engelma J: Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat Rev Cancer 2009; 9: 550-562.
25. Zhou L, Huang Y, Li J, et al: The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol 2010; 27: 255-261.
26. Chen J, Wang Q, Fu X, et al: Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol Res 2009; 39: 177-186.
27. Villanueva A, Chiang DY, Newell P, et al: Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008; 135: 1972-1983.
28. Treiber G: MTOR inhibitors for hepatocellular carcinoma: A forward-moving target. Expert Rev Anticancer Ther 2009; 9: 247-261.
29. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25. (Pubitemid 27076453)
30. Griffioen AW, Molema G: Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000; 52: 237-68. (Pubitemid 30368433)
31. Harper SJ, Bates DO: VEGF-A splicing: The key to anti-angiogenic therapeutics? Nat Rev Cancer 2008; 8: 880-887.
32. Fernandez M, Semela D, Bruix J, et al: Angiogenesis in liver disease. J Hepatol 2009; 50: 604-620.
33. Schoenleber SJ, Kurtz DM, Talwalkar JA, et al: Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: Systematic review and meta-analysis. Br J Cancer 2009; 100: 1385-1392.
34. Faivre S, Raymond E, Boucher E, et al: Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: An openlabel, multicenter, phase II study. Lancet Oncol 2009; 10: 794-800.
35. Zhu AX, Sahani DV, Duda DG, et al: Efficacy, safety, and potential biomarker of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study. J Clin Oncol 2009; 27: 3027-3035.
36. Forner A, Llovet JM, Bruix J: Sunitinib and the benefits of a negative study. Lancet Oncol 2009; 10: 743-744.
37. Raoul JL, Flinn RS, Kang YK, et al: An openlabel phase II study of first-and second-line treatment with brivanib in patients with hepatocellular carcinoma. J Clin Oncol 2009; 27(suppl):A4577.
38. Kanai F, Yoshida H, Tateishi R, et al: Final results of a phase I/II trial of the oral antiangiogenesis inhibitor TSU-68 in patients with advanced hepatocellular carcinoma. J Clin Oncol 2008; 26:A4589.
39. Ciardiello F, Tortora G: EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-1174.
40. Buckley AF, Burgart LJ, Sahai V, et al: Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol 2008; 129: 245-251. (Pubitemid 352029315)
41. Philip PA, Mahoney MR, Allmer C, et al: Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005; 23: 6657-6663. (Pubitemid 46190260)
42. Thomas MB, Chadhal R, Glover K, et al: Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007; 110: 1059-1066.
43. Thomas MB, Morris JS, Chadha R, et al: Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009; 27: 843-850.
44. Modified Folfox7/bevacizumab or modified Xelox/bevacizumab with or without erlotinib in first-line metastatic colorectal cancer (MCRC): Results of the feasibility phase of the DREAM-OPTIMOX3 study (GERCOR). J Clin Oncol. ASCO Annual Meeting Proceedings, 2007, part I, vol 25, No 18S, 4097.
45. Tournigand B, Samson W, Scheithauer C, et al: MFolfox-bevacizumab or Xelox-bevacizumab then bevacizumab alone or with erlotinib in first-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety analysis of DREAM study. J Clin Oncol 2009; 27: 15S, ASCO Annual Meeting, abstr No 4077C.
46. Hecht JR, Mitchell E, Chidiac T, et al: A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2008; 27: 672-680.
47. Azad NS, Posadas EM, Kwitkowski VE, et al: Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008; 26: 3709-3714.
48. Burris HA III, Hurwitz HI, Dees EC, et al: Phase I safety, pharmacokinetics, and clinical activity of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005; 23: 5305-5313. (Pubitemid 46206984)
49. Bekaii-Saab T, Markowitz J, Prescott N, et al: A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res 2009; 15: 5895-5901.
50. Zhu AX, Stuart K, Blaszkowsky LS, et al: Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007; 110: 581-589. (Pubitemid 47106147)
51. Comoglio PM, Giordano S, Trusolino L: Drug development of MET inhibitors: Targeting oncogene addiction and expedience. Nat Rev Drug Disc 2008; 7: 501-516.
52. Scharf JG, Braulke T: The role of the IGF axis in hepatocarcinogenesis. Horm Metab Res 2003; 35: 685-693. (Pubitemid 38058172)
53. Chen YW, Boyartchuk V, Lewis BC: Differential roles of insulin-like growth factor receptor-and insulin receptor-mediated signaling in the phenotypes of hepatocellular carcinoma cells. Neoplasia 2009; 11: 835-845.
54. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
55. Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
56. Kudo M: Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma in Japan, including its impact on complete remission. Oncology 2010; 78(suppl 1):154-166.
57. Kudo M, Imanaka K, Chida N, et al: Phase III study of sorafenib after transarterial chemoembolization in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011, in press.
58. Murata K, Suzuki H, Okano H, et al: Hypoxia-induced des-α- carboxyprothrombin production in hepatocellular carcinoma. Int J Clin Oncol 2010; 36: 161-170.
59. Ueshima K, Kudo M, Takita M, Nagai T, Tatsumi C, Ueda T, Kitai S, Ishikawa E, Yada N, Inoue T, Hagiwara S, Minami Y, Chung H, Sakurai T: Des-α-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma. Dig Dis 2011;29:321-325.
60. Kudo M: The 2008 Okuda Lecture. Management of hepatocellular carcinoma: From surveillance to molecular-targeted therapy. J Gastroenterol Hepatol 2010; 25: 439-452.
61. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M; for the HCC Panel of Japan Society of Hepatology: Management of hepatocellular carcinoma in Japan: Consensusbased clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011;29:339-364.
62. Abou-Alfa GK, Schwartz L, Ricci S, et al: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-4300. (Pubitemid 46630787)
63. Toh H, Chen PJ, Carr BI, et al: A phase II study of ABT-869 in hepatocellular carcinoma: Interim analysis. J Clin Oncol 2009; 27: 15S, suppl, A4581.
64. Siegel AB, Cohen EI, Ocean A, et al: Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008; 26: 2992-2998.
65. O'Dwyer PJ, Giantonio BJ, Levy DE, et al: Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group's Study E1203. J Clin Oncol 2006; 24: 18S, suppl, A4143.
66. Ramanathan RK, Belani CP, Singh DA, et al: A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 2009; 64: 777-783.